Outcomes of interferon α and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases

Gut

Volumn 52, Issue 11, 2003, Pages 1644-1648

  Hui, C K ^a,b   Monto, A ^c   Belaye, T ^c   Lau, E ^c   Wright, T L ^c  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DETERIORATION; DISEASE COURSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0242298192     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.11.1644     Document Type: Article

References (28)

1. Alter M, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62.
2. Di Bisceglie A, Goodman ZD, Ishak KG, et al. Long-term clinical and histopathological follow-up of chronic post-transfusion hepatitis. Hepatology 1991;14:969-74.
3. Seeff L, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung and Blood Institute Study Group. N Engl J Med 1992;327:1906-11.
4. Dienstog JL, Alter HJ. Non-A, non-B hepatitis: evolving epidemiologic and clinical perspective. Semin Liver Dis 1996;6:67-81.
5. Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 2002;36:S179-84.
6. Morsica G, Chemello L, Cavalletto B, et al. Hepatitis C viremia and liver disease in symptom free individuals with anti-HCV. Lancet 1992;340:697-8.
7. Naito M, Hayashi N, Hagiwara H, et al. Serum hepatitis C virus RNA quantity and histological features of hepatitis C virus carriers with persistently normal ALT levels. Hepatology 1994;19:871-5.
8. Prieto M, Olaso V, Verdu C, et al. Does the healthy hepatitis C virus carrier state really exists? An analysis using polymerase chain reaction. Hepatology 1995;22:413-17.
9. Silini E, Bono F, Cividini A, et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 1995;21:285-90.
10. Bruno S, Rossi S, Petroni L, et al. Normal aminotransferase concentrations in patients with antibodies to hepatitis C virus. BMJ 1994;308:679.
11. Yuki N, Hayashi N, Takehara T, et al. Serum hepatitis C virus RNA levels and liver injury in volunteer blood donors. Am J Gastroenterol 1994;89:1462-6.
12. Shakil AO, Conry-Cantilena C, Alter HJ, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic and histologic features. Ann Intern Med 1995;123:330-7.
13. Shindo M, Arai K, Sokawa Y, et al. The virological and histological states of anti-hepatitis C virus-positive subjects with normal liver biochemical values. Hepatology 1995;22:418-25.
14. Irving WL, Neal KR, Underwood JCE, et al. Chronic hepatitis in the United Kingdom and blood donors infected with hepatitis C virus. BMJ 1994;308:695-6.
15. Van Thiel DH, Caraceni P, Molloy PJ, et al. Chronic hepatitis C in patients with normal or near-normal alanine transferase levels: the role of interferon alpha-2b therapy. J Hepatol 1995;23:503-8.
16. Sangiovanni A, Morales R, Spinzi G, et al. Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study. Hepatology 1998;27:853-6.
17. Batts KP, Ludwig J. Chronic hepatitis: An update on terminology and reporting. Am J Surg Pathol 1995;19:1409-17.
18. Rossini A, Ravaggi A, Biasi L, et al. Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis. Hepatology 1997;26:1012-17.
19. Gordon SC, Fang JW, Silverman AL, et al. The significance of baseline serum aminotransferase on pretreatment disease characteristics and response to antiviral therapy in chronic hepatitis C. Hepatology 2000;32:400-4.
20. Lee SS, Sherman M. Pilot study on interferon-α and ribavirin treatment in patients with chronic hepatitis C and normal transaminase values. J Virol Hepat 2001;8:202-5.
21. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-92.
22. Poynard T, Marcellin P, Lee SS, et al. Randomized trial of interferon alpha 2b plus ribavirin for 48 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
23. Fried MW, Shiffman ML, Reddy RK, et al. Pegylated interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
24. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-65.
25. National Institute of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002-June 10-12, 2002. Hepatology 2002;36:S3-21.
26. Persico M, Persico E, Suozzo R, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000;118:760-4.
27. Martinot-Peignoux M, Boyer N, Cazals-Hatem D, et al. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology 2001;34:1000-5.
28. Di Bisceglie A. Chronic hepatitis C viral infection in patients with normal serum alanine aminotransferase. Am J Med 1999;107(suppl 6B):53S-55S.